Akero, Novo, MASH, AstraZeneca, Roche: Readout Newsletter

Akero, Novo, MASH, AstraZeneca, Roche: Readout Newsletter


Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. The M&A streak continues. Read on for the news today.

Novo to buy MASH drugmaker Akero Therapeutics

Novo Nordisk said this morning that it will buy Akero Therapeutics, the developer of a drug to treat the liver disease known as MASH, for up to $5.2 billion. 

STAT+ Exclusive Story

STAT+





This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *